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Treatment of intrahepatic congenital portosystemic shunts in dogs: a 16 
systematic review 17 
 18 
Objectives: To establish the evidence base for the treatment of intrahepatic congenital 19 
portosystemic shunts (CPSS) in dogs.  20 
Methods: A systematic review of the literature relating to the treatment of intrahepatic 21 
CPSS in dogs was performed. Studies were filtered for evidence to answer the question 22 
“Which of the treatment options for intrahepatic CPSS in dogs offers the best short and 23 
long term outcome?” Studies were assigned a level of evidence based on a system 24 
published by the Oxford Centre for Evidence-Based Medicine. 25 
Results: Thirty-two studies were included in the review. Twenty-six provided level 4 26 
evidence and six provided level 5 evidence. There were no level 1, 2 or 3 studies. One 27 
study compared surgical treatment with medical management and one study compared 28 
suture ligation with ameroid constrictor placement. The remaining studies were case 29 
series describing the outcome for one treatment only. There was considerable variation 30 
between studies in terms of the method and timings of assessment of short and long-31 
term outcome, making direct comparison challenging. 32 
Clinical Significance: The evidence for the treatment of intrahepatic CPSS in dogs is 33 
weak, with only two studies directly comparing treatments. There is a lack of evidence 34 
of short and long-term outcomes on which to base firm clinical decisions. Further 35 
research should aim to produce a consistent method of outcome assessment and 36 
compare different treatment options. 37 
 38 
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Introduction 39 
A variety of treatments have been recommended for dogs with intrahepatic congenital 40 
portosystemic shunts (CPSS) (White et al. 1998, Hunt et al. 2004, Adin et al. 2006, Mehl 41 
et al. 2007, Berent and Tobias 2009, Weisse et al. 2014). Surgical intervention to 42 
attenuate the abnormal vessel either acutely or gradually is recommended for most 43 
dogs (Berent and Tobias 2009, Greenhalgh et al. 2014). By improving or restoring 44 
normal portal blood flow this typically results in resolution of clinical signs and 45 
improvement in biochemical parameters (Breznock et al. 1983, White et al. 1998). 46 
However, incomplete treatment because of persistent shunting or the development of 47 
multiple acquired shunts can result in ongoing or recurrent clinical signs (White et al. 48 
1998, Kummeling et al. 2004). Long-term medical management can also be used in 49 
animals where surgery is not available or is declined by the owner (Watson and 50 
Herrtage 1998, Greenhalgh et al. 2014).  51 
 52 
For many years, surgical attenuation of intrahepatic CPSS was the recommended 53 
treatment either using suture ligation, an ameroid constrictor, a cellophane band or a 54 
hydraulic occluder (Komtebedde et al. 1991, White et al. 1998, Papazoglou et al. 2002, 55 
Hunt et al. 2004, Adin et al. 2006, Mehl et al. 2007). However, it is recognised that 56 
intrahepatic CPSS can be more challenging to treat surgically than extrahepatic CPSS 57 
due to the location of the abnormal vessel within the liver parenchyma. Different 58 
strategies have been used to access the CPSS surgically to allow attenuation and the 59 
method employed is dependent on the morphology of the CPSS. Extravascular surgery 60 
involves dissection of the CPSS itself, the draining hepatic vein or the portal vein branch 61 
supplying it. Reports have also described the use of intravascular techniques to allow 62 
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attenuation of some IHCPSS, which is technically more demanding (Breznock et al. 63 
1983, Hunt et al. 1996, White et al. 1998). Concern over peri-operative complications 64 
and mortality has prompted the development of a minimally invasive treatment for 65 
intrahepatic CPSS (Bussadori et al. 2008, Weisse et al. 2014). Endovascular coil 66 
embolization with interventional radiology has been recommended to reduce 67 
complications and mortality associated with traditional surgical techniques (Weisse et 68 
al. 2014). Whilst many authorities recommend certain treatments over others there is a 69 
lack of a consensus on which is best. Establishing the evidence base for the treatment of 70 
dogs with intrahepatic CPSS is very important to allow owners and veterinary surgeons 71 
to make informed decisions. 72 
 73 
A previous review assessed the evidence base for the surgical treatment of extrahepatic 74 
CPSS in dogs (Tivers et al. 2012). Published studies on CPSS in dogs were graded on the 75 
level of evidence that they provided to answer this question. This review found that the 76 
evidence base for the treatment of extrahepatic CPSS in dogs was weak, meaning that it 77 
was not possible to make firm recommendations.  78 
 79 
We therefore undertook a systematic review of the current literature to determine the 80 
evidence base for the treatment of intrahepatic CPSS in dogs. The aim of the study was 81 
to assess the evidence base with a view to identifying whether one treatment could be 82 
recommended over another based on short and / or long-term outcome.  83 
 84 
Materials and Methods 85 
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The following question was formulated to establish the evidence base for the treatment 86 
of intrahepatic CPSS in dogs: “Which of the treatment options for intrahepatic CPSS in 87 
dogs offers the best short and long term outcome?” An online bibliographic search was 88 
performed in November 2016 for studies relating to the treatment of intrahepatic CPSS 89 
in dogs. The search utilised the PubMed (http://www.pubmed.gov/) and ISI Web of 90 
Science (http://wok.mimas.ac.uk/) databases. Databases were searched using the 91 
following terms: (portosystemic shunt OR portocaval shunt OR portovascular anomaly 92 
OR portosystemic communication OR intrahepatic vascular anomaly OR intrahepatic 93 
shunt) AND (dog OR canine OR canid) AND (treatment OR outcome OR mortality OR 94 
morbidity OR complications).  Following this process, the databases were also searched 95 
using the following terms: (portosystemic shunt(s) OR portocaval shunt(s)) AND dog. 96 
This was to ensure that any studies that were not captured in the original, more specific 97 
search, were included. 98 
Analysis was restricted to the English language veterinary literature reporting 99 
information on the treatment of intrahepatic CPSS in dogs. The abstracts were reviewed 100 
for relevance to the question. Studies were excluded if they were experimental, 101 
described only acquired PSS or extrahepatic CPSS, were case reports or small case 102 
series (less than five dogs) or did not provide any detail regarding outcome (e.g. studies 103 
describing diagnostic tests, etc.).  104 
Studies meeting these criteria were reviewed by the primary author and were assigned 105 
a level of evidence based on the system published by the Oxford Centre for Evidence-106 
Based Medicine (OCEBM Levels of Evidence Working Group 2017) (Table 1). 107 
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The following data was recorded from each study: the type of study described (i.e. case 108 
series, cohort study, etc.); the number of dogs included; the treatment used; the short-109 
term outcome in terms of mortality rate; the long-term outcome including duration of 110 
follow-up and method of assessment. It was anticipated that the type of outcomes 111 
reported, particularly for long-term outcome, would vary between studies. Therefore, 112 
the method of outcome assessment, the timing and the result were also recorded. 113 
 114 
Results 115 
Thirty-two studies were identified as providing relevant information for answering the 116 
question (Table 2). Twenty-six were classified as level 4 and the remaining six were 117 
classified as level 5. There were no level 1, 2 or 3 studies.  118 
Direct comparison of different treatments 119 
Three studies were identified that compared the outcome of two different treatments 120 
(Mehl et al. 2007, Greenhalgh et al. 2010, Greenhalgh et al. 2014). Two of these studies 121 
described a prospective comparison of medical and surgical management in the same 122 
cohort of dogs so the more recent paper was chosen to represent this dataset 123 
(Greenhalgh et al. 2010, Greenhalgh et al. 2014). This was a prospective cohort study 124 
that directly compared the short and long-term outcome for 27 dogs treated with 125 
medical management and 97 dogs treated with surgical attenuation (Greenhalgh et al. 126 
2014). The study included 110 dogs with extrahepatic CPSS and 14 dogs with 127 
intrahepatic CPSS. Eight of the intrahepatic CPSS dogs had surgery and six were treated 128 
medically. Long-term follow-up was obtained by owner questionnaires and telephone 129 
calls with owners and the referring veterinary surgeons. Twenty-four out of 27 dogs 130 
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(89%) treated medically died or were euthanised during the follow up period. The 131 
median survival time was 836 days. Twenty-one out of 97 dogs (22%) treated surgically 132 
died or were euthanised during the follow-up period. This included five dogs (5.2%) 133 
that died in the peri-operative period (7 days after surgery), including one dog that 134 
died following a second surgery. Seven dogs (7.2%) in the surgery group were lost to 135 
follow-up. It was not possible to estimate median survival for the surgically treated dogs 136 
due to the large number that were still alive at follow-up. The survival rate for surgically 137 
treated dogs was statistically significantly greater than that of those managed medically. 138 
There was no significant effect of shunt type (extrahepatic versus intrahepatic) on 139 
survival. The frequency of ongoing clinical signs was statistically significantly better for 140 
surgically treated dogs (completed questionnaires from 46/75 dogs alive) compared 141 
with medically treated dogs (completed questionnaires from 6/9 dogs alive) 4-7 years 142 
after study entry.  143 
 144 
There was a single retrospective study comparing the outcome for dogs with left 145 
divisional intrahepatic CPSS treated with suture ligation and ameroid constrictors 146 
(Mehl et al. 2007). This study reported the short and long-term outcomes for 17 dogs 147 
treated with partial ligation with 11 dogs treated with ameroid constrictors. Two dogs 148 
in the partial ligation group (11.8%) and one dog in the ameroid constrictor group 149 
(9.1%) suffered postoperative complications. Overall one dog died in the partial ligation 150 
group (5.9%) due to a severe coagulopathy and one dog died in the ameroid constrictor 151 
group (9.1%) due to post-operative seizures. There was no significant difference in the 152 
surgical morbidity or mortality between the two techniques. A proportion of the dogs 153 
had portal scintigraphy performed at 6-10 weeks’ post-surgery. Persistent shunting was 154 
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identified in 7/8 dogs in the partial ligation group (87.5%) and in 3/7 dogs in the 155 
ameroid constrictor group (42.9%). There was no statistically significant difference in 156 
the proportion of dogs with persistent shunting on scintigraphy between the two 157 
groups. Long-term clinical outcome was assessed via a telephone questionnaire with 158 
the owner or referring veterinary surgeon. An excellent outcome was defined as “dogs 159 
that were free of any clinical signs and not on any special dietary requirements or 160 
medications”, a good outcome included “dogs that were perceived to be clinically 161 
normal according to the owners, and were maintained on low protein diets and/or 162 
medical therapy” and a poor outcome included “dogs that showed no improvement 163 
after surgery and remained clinical for a PSS or had worsening clinical signs” (Mehl et 164 
al. 2007). Outcome was obtained for 13 dogs in the partial ligation group at a median of 165 
50 months (range 6-122) post-surgery and for 10 dogs in the ameroid constrictor group 166 
at a median of 28.5 months (range 14-54) post-surgery. In the partial ligation group 167 
outcome was excellent in 12/13 (92%) and good in 1/13 (8%). The dog with a good 168 
outcome had persistent flow through the shunt. A second surgery was performed and 169 
complete attenuation was achieved, resulting in an excellent outcome for this dog. In 170 
the ameroid constrictor group the outcome was excellent in 2/10 (20%), good in 5/10 171 
(50%) and poor in 3/10 (30%). The three dogs with a poor outcome had all been 172 
euthanised due to signs of hepatic insufficiency at 14, 19 and 27 months post-surgery. 173 
The long-term outcome, in terms of grade, was significantly better in dogs treated with 174 
suture ligation compared with ameroid constrictors.  175 
 176 
Case series reporting the outcome for one treatment 177 
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There were 21 studies that were case series reporting the short and / or long-term 178 
outcome for a single treatment for intrahepatic CPSS in dogs. Two of these were 179 
prospective studies and the remainder were retrospective. Sixteen studies described 180 
various types of surgical treatment and these are summarised in Table 3. Four studies 181 
described endovascular coil embolization and these are summarised in Table 4. One 182 
study described medical management and this is summarised in Table 5. 183 
An additional eight studies were identified that were level 5 evidence (Table 2). Whilst 184 
they contained some information on outcome this was either insufficient to justify their 185 
inclusion or it was not possible to differentiate the outcome data for dogs with 186 
intrahepatic CPSS from those with extrahepatic CPSS. 187 
A summary of short and long-term outcome for different surgical procedures (including 188 
endovascular coil embolization) is presented in Table 6. For suture ligation and 189 
endovascular coil embolization this included the larger studies only. 190 
 191 
Discussion 192 
This systematic review of the literature regarding the treatment of intrahepatic CPSS in 193 
dogs reveals that the evidence base for recommending treatments is very weak. When 194 
attempting to determine the most effective treatment or intervention for a given disease 195 
or condition the decision should ideally be based on the most reliable evidence 196 
available. There are several systems available that can be used to rank evidence 197 
(Howick et al. 2017).  A previous review of the evidence base for the treatment of 198 
extrahepatic CPSS in dogs used a modification of an existing grading system (Tivers et 199 
al. 2012). This system was published by the Oxford Centre for Evidence-Based Medicine 200 
but has subsequently been revised (OCEBM Levels of Evidence Working Group 2017). 201 
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The revised version was designed so that the structure reflects clinical decision making 202 
and is simpler, refraining from making definitive recommendations (Howick et al. 203 
2017). Importantly, unlike other systems, it is suitable for use when no systematic 204 
reviews are available (Howick et al. 2017). The current review used the revised version 205 
as we believed that these modifications made it more suitable for application to the 206 
veterinary literature.  207 
 208 
It is generally accepted that systematic reviews of randomised controlled trials (RCTs) 209 
provide the most reliable evidence. Unfortunately, RCTs are very uncommon in the 210 
veterinary literature. Perhaps unsurprisingly, the current review did not identify any 211 
level 1, 2 or 3 studies reporting the outcome for dogs with intrahepatic CPSS. Most 212 
studies were level 4 case series describing the outcome for a single treatment. 213 
Therefore, the evidence that is available to make decisions on which treatment to use is 214 
very limited. Several studies were level 5, providing minimal evidence to answer the 215 
question. These studies either did not provide any useful information regarding 216 
outcome or provided combined outcome data for intrahepatic and extrahepatic CPSS 217 
and it was not possible to separate these out. This is not intended as a criticism of these 218 
studies, rather that they did not provide good evidence for the question asked in the 219 
current review. 220 
 221 
We did not attempt to categorise the level 4 studies further, although Table 2 does show 222 
the types of study represented. There was one prospective cohort study that compared 223 
the outcome of surgical treatment with medical treatment (Greenhalgh et al. 2014). The 224 
results of this study strongly support the use of surgical treatment over medical 225 
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management for most dogs. However, it should be recognised that although this study 226 
was prospective, it was not randomised and there may have been significant selection 227 
bias affecting the distribution of dogs into the two treatment groups. In addition, the 228 
study included dogs treated with a variety of techniques and it is therefore difficult to 229 
determine the effect of a given surgery. Importantly, the study included dogs with both 230 
intrahepatic CPSS and extrahepatic CPSS and it was not possible to separate the data for 231 
the two groups in detail (although morphology did not influence survival). There was 232 
also a relatively small number of dogs with intrahepatic CPSS, with eight treated 233 
surgically and six managed medically. 234 
 235 
A single study retrospectively compared dogs treated with partial suture ligation with 236 
those treated with ameroid constrictor placement (Mehl et al. 2007). This study found 237 
that there was no difference in peri-operative complications and mortality but that the 238 
long-term outcome was significantly better for those dogs treated with suture ligation. 239 
This study had good long-term follow-up but there were relatively small numbers of 240 
dogs in both groups (17 suture ligation and 11 ameroid constrictor). It is noteworthy 241 
that this report only described dogs with one type of intrahepatic CPSS (left divisional). 242 
It is therefore unclear if these results can be extrapolated to other morphologies of 243 
intrahepatic CPSS. 244 
 245 
The remaining studies were case series describing the outcome for one type of 246 
treatment, including surgical techniques, endovascular coil embolization and medical 247 
management (summarised in Tables 3, 4 and 5). However, several studies reported 248 
more than one surgical technique, which makes drawing firm conclusions on individual 249 
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treatments difficult. Some studies described dogs that had suture ligation, intravascular 250 
attenuation and / or the placement of mattress sutures or hemoclips (Breznock et al. 251 
1983, Komtebedde et al. 1991, White et al. 1998). It is arguable that these can be 252 
considered as one group as they are techniques providing acute attenuation and the 253 
choice is dictated largely by the morphology of the shunt. However, it is well recognised 254 
that intravascular techniques are more complex and technically demanding and their 255 
use in some case series and not in others may have skewed the results. Two other 256 
studies report dogs treated with a variety of techniques including both acute and 257 
gradual attenuation methods and this makes interpretation of these results difficult 258 
(Papazoglou et al. 2002, Parker et al. 2008).  259 
 260 
Overall, the studies identified in this review provide a considerable amount of 261 
information but it is difficult to directly compare them due to the wide variation in the 262 
way that outcome has been measured and reported. Short-term outcome can be 263 
considered easier to quantify, particularly in terms of morbidity and mortality. 264 
However, studies vary in the type of complications that are reported and the time frame 265 
in terms of intra, peri and post-operative periods. We did not record complication rates 266 
for most studies due this variability. Mortality is a more absolute variable, although the 267 
time frame for peri or post-operative mortality can range from the duration of 268 
hospitalisation to 30 days’ post-surgery. Some small studies report a mortality rate of 269 
0% but this is likely to reflect the number of dogs included rather than the absolute 270 
success of the procedure. A summary of the short-term outcome according to surgical 271 
procedure is presented in Table 6. This is particularly limited by the small numbers of 272 
dogs treated with ameroid constrictors and cellophane bands, making direct 273 
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comparison from this table challenging. Surgical attenuation of intrahepatic CPSS has 274 
been associated with a relatively high rate of peri-operative complications and death. 275 
Two studies, which are commonly referenced, were not included in the Table 6, one due 276 
to relatively small numbers (Komtebedde et al. 1991) and one due to the inclusion of 277 
several different surgical techniques (Papazoglou et al. 2002). These studies reported 278 
complication rates of 77% and 47% respectively, which were greater than those 279 
included in Table 6. These studies also reported a mortality rate of 23.1% and 12.5% 280 
respectively, both within the range reported in Table 6. Endovascular coil embolization 281 
is recommended as a minimally invasive treatment for intrahepatic CPSS to reduce the 282 
morbidity and mortality associated with open surgery. A large study of 95 dogs treated 283 
with endovascular coil embolization reported a post-operative complication rate of 284 
18.9% and a mortality of 5.3%. The complication rate for this group of dogs is 285 
somewhat unclear as both intra-operative and post-operative complications are 286 
reported separately and complications are reported for 111 procedures, including 287 
repeat procedures in several dogs and five animals that did not have coils placed due to 288 
evidence of portal hypertension.  289 
 290 
The long-term outcome of intrahepatic CPSS treatment is more challenging to assess 291 
than the short-term outcome. A variety of outcome measures have been used, including 292 
clinical assessment, owner assessment, serum bile acids or ammonia tolerance testing, 293 
ultrasound and scintigraphy (White et al. 1998, Hunt et al. 2004, Kummeling et al. 2004, 294 
Adin et al. 2006, Mehl et al. 2007, Weisse et al. 2014). However, it is unclear which of 295 
these represent the most appropriate or reliable assessment. Table 6 also summarises 296 
the long-term outcome of the different treatments, showing that all have relatively 297 
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similar results. The wide variation in both the method of long term follow up and the 298 
definition of an ‘excellent’ or ‘good’ outcome make direct comparison for the different 299 
techniques challenging. If we consider a poor outcome then we can summarise the data 300 
as follows.  For dogs treated with suture ligation 0-16.2% of dogs had a poor outcome 301 
with recurrent or persistent signs and / or shunting at an average of 16-50 months’ 302 
post-surgery (including those that had repeat surgery) (White et al. 1998, Kummeling et 303 
al. 2004, Mehl et al. 2007). For dogs treated with ameroid constrictors 12.5-30% had a 304 
poor outcome, with euthanasia due to persistence or recurrent clinical sings at an 305 
average of 28.5-38.3 months’ post-surgery (Bright et al. 2006, Mehl et al. 2007). This is 306 
compared to coil embolization where 19% of dogs had a poor outcome with continued 307 
or worsening clinical signs despite medical management or surgical related death at a 308 
median of 32.1 months post-treatment (Weisse et al. 2014). Similarly, it should be 309 
recognised that this information is based on a small number of dogs treated with 310 
ameroid constrictors and a single study, albeit with a large number of dogs, treated with 311 
coil embolization.  312 
 313 
This review highlights the relative lack of information on long-term outcome for 314 
intrahepatic CPSS treatment. Further information is needed to determine which 315 
treatment gives the best long-term outcome. Currently, the ideal end-point for CPSS 316 
occlusion is unclear. It is unknown whether the aim of surgery should be to achieve full 317 
attenuation in every animal or whether some degree of persistent shunting is 318 
acceptable. This should be addressed so that the most appropriate treatment can be 319 
recommended to achieve a good long-term outcome. Further comparative clinical 320 
studies are essential to determine the precise pros and cons of different treatment 321 
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options. Importantly, we need studies that compare both the short-term morbidity and 322 
mortality and the long-term outcome in terms of quality of life. Ideally studies would 323 
compare different types of surgical attenuation with each other and coil embolization 324 
based on random allocation. However, different shunt morphology may also influence 325 
the results of different surgical techniques and therefore, it may be sensible to compare 326 
treatments for each broad shunt morphology. There is a need for studies to include 327 
larger numbers of dogs to increase their reliability. This may be best achieved through 328 
collaboration between several centres. 329 
  330 
There are other factors besides risk of morbidity and mortality that will influence 331 
decision-making, which were not assessed as part of the current review. These include 332 
availability of equipment and expertise, financial considerations and client and surgeon 333 
preference. Importantly there may be factors relating to the individual dog that may 334 
influence choice of treatment, particularly the morphology of the CPSS. As knowledge 335 
about the morphology of intrahepatic CPSS increases with the use of computed 336 
tomography (CT) it may be that we can identify some animals that would benefit 337 
specifically from surgical treatment and some specifically from endovascular coil 338 
embolization, although this is unproven. 339 
 340 
There are still many unanswered questions regarding the management of dogs with 341 
intrahepatic CPSS. Large randomised prospective studies are needed to compare 342 
treatments to determine which are associated with the best outcome for dogs. Further 343 
investigation is also needed to develop consistent and validated outcome measures. 344 
 345 
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